Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ LAReferencia - Red F...arrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
CONICET Digital
Article . 2013
License: CC BY NC SA
Data sources: CONICET Digital
versions View all 2 versions
addClaim

Amoxicilina: la existencia de diferentes presentaciones comerciales como factor determinante del uso irracional del medicamento

Authors: Domínguez, Eiana Belén; Fernández, Pedro Nicolás; Giménez, José Florentino; Gerometta, Rosana María del Rosario;

Amoxicilina: la existencia de diferentes presentaciones comerciales como factor determinante del uso irracional del medicamento

Abstract

INTRODUCCION: La Amoxicilina, un antibiótico de amplio espectro, según consensos internacionales, debe ser usada en esquemas de 500 mg cada 8 hs, 750 mg cada 12 hs, 875 mg cada 12 hs, ó 1000 mg cada 12 hs por 7 a 10 días. En la actualidad, los esquemas impuestos por las diferentes presentaciones comerciales, existentes en la República Argentina, generalmente no se ajustan a estos supuestos. Esto podría tener consecuencias negativas en el uso racional del medicamento. OBJETIVOS: Conocer las presentaciones comerciales de Amoxicilina en comprimidos existentes actualmente en el mercado argentino, contrastar la posibilidad de completar el esquema terapéutico con el uso propuesto por las diferentes presentaciones y relacionar esto con el uso irracional del medicamento. MATERIALES Y METODOS: Se realizó el estudio en base al análisis de diferentes presentaciones comerciales de Amoxicilina en comprimidos del mercado argentino obtenidos de motores de búsqueda informáticos y material bibliográfico. Se procesaron los datos en planilla de cálculos y se realizaron análisis estadísticos. RESULTADOS: Existen 20 laboratorios, 74 productos y 13 tipos de presentaciones comerciales según dosis y cantidad de comprimidos. Se determinó que 5 tipos de presentaciones comerciales (26%) se ajustan al esquema de tratamiento aceptado y 8 tipos (74%) no concuerdan con el esquema terapéutico consensuado. DISCUSION: Del total de los tipos de presentaciones de Amoxicilina, la mayoría (74%) no cumple el esquema de tratamiento, un porcentaje menor (26%) se ajusta a las normas internacionales de uso racional de Amoxicilina. CONCLUSION: El uso irracional del medicamento por esquemas incompletos podría derivar en mayor resistencia bacteriana, reacciones adversas al medicamento, incumplimiento de los días de tratamiento necesarios y la necesidad de comprar más de un envase, encareciendo el tratamiento. El motivo por el que existe un uso indebido podría no ser solo por la gran cantidad de presentaciones comerciales sino también por el desconocimiento de médicos sobre los tipos de presentaciones existentes en el mercado y la falta de información impartida al profesional para evitar esto. Son pertinentes más estudios sobre el uso racional de Amoxicilina para evitar estas posibles consecuencias.

INTRODUCTION: Amoxicillin, a broad-spectrum antibiotic, according to international consensus, should be used in schemes of 500 mg every 8 hours, 750 mg every 12 hours, 875 mg every 12 hours, or 1000 mg every 12 hours during 7 to 10 days. Currently, the schemes of different commercial presentations, existing in Argentina, don´t correspond to these assumptions. This may have a negative impact on rational drug use. OBJECTIVES: To determine the commercial tablets presentations currently on the Argentine market, test the possibility to finish the therapeutic regimen with the use proposed by the different presentations and relate this to the use irrational use of medicine. MATERIALS AND METHODS: The study was based on the analysis of different commercial presentations of Amoxicillin in the Argentine market tablets obtained from computer search engine and bibliography. The data was processed in spreadsheet and were performed statistical analyzes. RESULTS: There are 20 companies, 74 products and 13 types of commercial presentations as dosage and number of pills. It was determined that five types of business presentations (26%) are in accordance with accepted treatment regimen and 8 types (74%) do not agree with the consensus treatment regimen. DISCUSSION: Of all the types of presentations of Amoxicillin, the majority (74%) does not meet the treatment schedule, a smaller percentage (26%) are conform to international standards of rational use of Amoxicillin. CONCLUSION: The irrational use of medicine could result in incomplete schemes increased bacterial resistance, adverse drug reactions, breach of treatment day required, and to buy more than one container, that casuesmore expensive treatment. The reason that there is abuse may be is not because the many business presentations but also by the lack of doctors on the types of presentations on the market and the lack of information given to professional to avoid this. Further studies are relevant on the rational use of Amoxicillin to avoid these potential consequences.

Fil: Gerometta, Rosana María del Rosario. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina

Fil: Fernández, Pedro Nicolás. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina

Fil: Giménez, José Florentino. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina

Fil: Domínguez, Eiana Belén. Universidad Nacional del Nordeste. Facultad de Medicina; Argentina

Country
Argentina
Keywords

https://purl.org/becyt/ford/3.1, ANTIBIOTICOS, AMOXICILINA, CONSUMO, https://purl.org/becyt/ford/3, USO

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    0
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Average
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Average
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Average
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
0
Average
Average
Average
Green